Vivozon Pharmaceutical announced on the 6th that its non-narcotic analgesic 'Anapra' (ingredient name: ophiranjeline) is set to be launched domestically in the third quarter.
Anapra injection is a non-narcotic analgesic used for the management of moderate to severe acute pain after surgery. Vivozon Pharmaceutical secured statistical significance in a domestic Phase 3 clinical trial targeting patients after laparoscopic colectomy and obtained approval from the Ministry of Food and Drug Safety in December of last year as the 38th domestically produced new drug.
The company is currently conducting global Phase 3 clinical trials for Anapra, aiming for approval from the U.S. Food and Drug Administration (FDA). Anapra has received Fast Track designation from the FDA. In the future, the company plans to pursue technology transfers and exports of finished goods to the U.S., Europe, and Japan.
Vivozon Pharmaceutical is also developing a range of follow-up new drug candidates for pain, addiction, degenerative brain diseases, using its proprietary multi-target compound discovery platform technology. These include the oral analgesic 'VVZ-2471', which is in Phase 2 clinical trials, and the Parkinson's disease treatment 'VVZ-3416', which has entered preparation for clinical entry.
A company official noted, "There is a growing unmet demand for non-narcotic analgesics globally, along with a trend toward stricter regulations on abuse," adding, "Once Anapra's sales expand next year, revenue improvement will also be possible."